BofA/Merrill Lynch Upgrades BioCryst Pharma (BCRX) to Neutral
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $4.54 +0.89%
Rating Summary:
17 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 18 | New: 16
Rating Summary:
17 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 18 | New: 16
Join SI Premium – FREE
BofA/Merrill Lynch upgraded BioCryst Pharma (NASDAQ: BCRX) from Underperform to Neutral with a price target of $12.00 (from $8.00).
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $9.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Bank of America (BAC) to Outperform, 'Underearning Firms Shouldn’t Trade at a Discount'
- Canfor Pulp Products (CFX:CN) (CFPUF) PT Raised to Cdn$2.75 at Raymond James
- BioCryst Pharma (BCRX) Announces Approval of ORLADEYO in Brazil
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
